Nuwellis, Inc. Announces Third Quarter 2021 Financial Results
MINNEAPOLIS, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the third quarter ended September 30, 2021, which included the following highlights:
Generated $1.9 million in total revenue, representing a decline of 3% compared to the prior-year period
Generated $6.3 million in total revenue year-to-date through September 30, representing 16% growth compared to the prior-year period and a 52% increase above the comparable pre-pandemic period in 2019
Opened three new pediatric accounts in the third quarter, the largest quarterly addition in 2021
Announced R&D partnership with Koronis Biomedical Technologies Corporation (KBT) to design and develop a product for children under 20kg with limited kidney function, following a $1.7 million development grant from the National Institutes of Health
Completed an all-common stock capital raise of $10.0 million gross proceeds, ending the quarter with $28.4 million in cash and no debt
“Although the third quarter was a challenging environment due to COVID headwinds, we were able to continue adding new pediatric customers and drive increased utilization within our Critical Care business at key accounts,” said Nestor Jaramillo, CEO of Nuwellis. “Similar to previous cycles where COVID cases drop following spikes in geographic hot spots, we believe we will be able execute our operating plan and accelerate revenue growth in our key markets when the healthcare environment normalizes.”
Third Quarter 2021 Financial Results
Revenue for the third quarter of 2021 was $1.9 million, representing a decline of 3% compared to the prior-year period. This revenue decline was driven primarily by the cancellation of elective procedures and the change in protocol to minimize use of fluid resuscitation when treating critically ill COVID patients.
Critical Care revenue more than doubled compared to the prior-year period but declined sequentially due to COVID headwinds. The Company continues to see strong utilization from key accounts that rely heavily on the Aquadex System to treat non-COVID critically ill patients.
Pediatric revenue declined compared to the prior-year period due to a more difficult hospital operating environment. The Company opened three new pediatric accounts in the third quarter, its largest quarterly addition in 2021, a strong sign of the interest to use the therapy among pediatric institutions.
Heart Failure revenue increased compared to the prior year period but declined sequentially due a spike in COVID cases which negatively impacted patient behavior and access to hospitals.
Gross margin was 60.4% for the third quarter 2021, compared to 46.1% in the prior year period. The increase in gross margin was primarily due to favorable geographic and product mix.
Selling, general and administrative (“SG&A”) expenses for the third quarter of 2021 were $4.6 million, an increase of 9% compared to the prior-year period. The increase in SG&A was primarily due to our continued investment in sales and marketing activities, plus additional administrative costs. Research and development (“R&D”) expenses in the third quarter of 2021 were $1.7 million, an increase of 98% compared to the prior year period. The increase in R&D expenses was driven primarily by investments in new products, namely the new pediatric system, along with increased spending on clinical evidence, regulatory and reimbursement activity.
The net loss for the third quarter of 2021 was $5.3 million, compared to a net loss of $4.3 million in the prior year period reflecting the new investments made this year in product development and clinical evidence, as mentioned above.
Cash and cash equivalents were approximately $28.4 million as of September 30, 2021. During the third quarter of 2021, the Company completed an all-common stock capital raise of $10.0 million in gross proceeds.
Webcast and Conference Call Information
The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company’s performance. To access the live webcast, please visit http://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 1436426. An audio archive of the webcast will be available following the call at http://ir.nuwellis.com.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, MN, with a wholly-owned subsidiary in Ireland.
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2021 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
FINANCIAL STATEMENTS
NUWELLIS, INC. AND SUBSIDIARY
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited, in thousands, except per share amounts)
Three months ended | Nine months ended | |||||||||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||||||||||||||||
Net sales | $ | 1,853 | $ | 1,904 | $ | 6,279 | $ | 5,397 | ||||||||||||||||||||||
Cost of goods sold | 733 | 1,026 | 2,682 | 2,486 | ||||||||||||||||||||||||||
Gross profit | 1,120 | 878 | 3,597 | 2,911 | ||||||||||||||||||||||||||
Operating expenses: | ||||||||||||||||||||||||||||||
Selling, general and administrative | 4,645 | 4,264 | 14,945 | 13,034 | ||||||||||||||||||||||||||
Research and development | 1,726 | 871 | 3,847 | 2,620 | ||||||||||||||||||||||||||
Total operating expenses | 6,371 | 5,135 | 18,792 | 15,654 | ||||||||||||||||||||||||||
Loss from operations | (5,251 | ) | (4,257 | ) | (15,195) | (12,743 | ) | |||||||||||||||||||||||
Other income (expense), net | (19 | ) | — | (22 | ) | — | ||||||||||||||||||||||||
Loss before income taxes | (5,270 | ) | (4,257 | ) | (15,217 | ) | (12,743 | ) | ||||||||||||||||||||||
Income tax expense | (2 | ) | (3 | ) | (7 | ) | (7 | ) | ||||||||||||||||||||||
Net loss | $ | (5,272 | ) | $ | (4,260 | ) | $ | (15,224 | ) | $ | (12,750 | ) | ||||||||||||||||||
Basic and diluted loss per share | $ | (0.75) | $ | (2.08 | ) | $ | (2.72 | ) | $ | (11.27 | ) | |||||||||||||||||||
Weighted average shares outstanding – basic and diluted | 7,098 | 2,049 | 5,624 | 1,287 | ||||||||||||||||||||||||||
Other comprehensive loss: | ||||||||||||||||||||||||||||||
Foreign currency translation adjustments | $ | — | $ | (7 | ) | $ | (3 | ) | $ | (12 | ) | |||||||||||||||||||
Total comprehensive loss | $ | (5,272 | ) | $ | (4,267 | ) | $ | (15,227 | ) | $ | (12,762 | ) | ||||||||||||||||||
NUWELLIS, INC. AND SUBSIDIARY
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
September | December 31, | |||||||
ASSETS | (unaudited) | |||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 28,431 | $ | 14,437 | ||||
Accounts receivable | 1,069 | 905 | ||||||
Inventories | 2,805 | 2,957 | ||||||
Other current assets | 420 | 237 | ||||||
Total current assets | 32,725 | 18,536 | ||||||
Property, plant and equipment, net | 1,265 | 1,200 | ||||||
Operating lease right-of-use asset | 105 | 255 | ||||||
Other assets | — | 21 | ||||||
TOTAL ASSETS | $ | 34,095 | $ | 20,012 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 1,851 | $ | 1,097 | ||||
Accrued compensation | 1,771 | 2,192 | ||||||
Current portion of operating lease liability | 108 | 206 | ||||||
Current portion of finance lease liability | 27 | 24 | ||||||
Other current liabilities | 38 | 66 | ||||||
Total current liabilities | 3,795 | 3,585 | ||||||
Operating lease liability | — | 55 | ||||||
Finance lease liability | 33 | 54 | ||||||
Other Long-term liability | 286 | — | ||||||
Total liabilities | 4,114 | 3,694 | ||||||
Commitments and contingencies | ||||||||
Stockholders’ equity | ||||||||
Series A junior participating preferred stock as of September 30, 2021 and December 31, 2020, par value $0.0001 per share; authorized 30,000 shares, none outstanding | — | — | ||||||
Series F convertible preferred stock as of both September 30, 2021 and December 31, 2020, par value $0.0001 per share; authorized 127 shares, issued and outstanding 127 shares | — | — | ||||||
Preferred stock as of both September 30, 2021 and December 31, 2020, par value | — | — | ||||||
Common stock as of September 30, 2021 and December 31, 2020, par value | 1 | — | ||||||
Additional paid-in capital | 278,552 | 249,663 | ||||||
Accumulated other comprehensive loss: | ||||||||
Foreign currency translation adjustment | (10 | ) | (7 | ) | ||||
Accumulated deficit | (248,562 | ) | (233,338 | ) | ||||
Total stockholders’ equity | 29,981 | 16,318 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 34,095 | $ | 20,012 | ||||
NUWELLIS, INC. AND SUBSIDIARY
Condensed Consolidated Statements of Cash Flows
(unaudited, in thousands)
Nine months ended | ||||||||
2021 | 2020 | |||||||
Operating Activities: | ||||||||
Net loss | $ | (15,224 | ) | $ | (12,750 | ) | ||
Adjustments to reconcile net loss to cash flows used in operating activities: | ||||||||
Depreciation and amortization | 383 | 253 | ||||||
Stock-based compensation expense, net | 993 | 1,036 | ||||||
Loss on disposal of property and equipment | — | 46 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | (164 | ) | (249 | ) | ||||
Inventory | (105 | ) | (1,371 | ) | ||||
Other current assets | (183 | ) | (74 | ) | ||||
Other assets and liabilities | 279 | 112 | ||||||
Accounts payable and accrued expenses | 333 | (166 | ) | |||||
Net cash used in operating activities | (13,688 | ) | (13,163 | ) | ||||
Investing Activities: | ||||||||
Purchases of property and equipment | (191 | ) | (207 | ) | ||||
Net cash used in investing activities | (191 | ) | (207 | ) | ||||
Financing Activities: | ||||||||
Proceeds from public stock offerings, net | 27,896 | 25,949 | ||||||
Proceeds from warrant exercises | 1 | 4,115 | ||||||
Payments on finance lease liability | (21 | ) | (14 | ) | ||||
Net cash provided by financing activities | 27,876 | 30,050 | ||||||
Effect of exchange rate changes on cash | (3 | ) | (12 | ) | ||||
Net increase in cash and cash equivalents | 13,994 | 16,668 | ||||||
Cash and cash equivalents - beginning of period | 14,437 | 1,279 | ||||||
Cash and cash equivalents - end of period | $ | 28,431 | $ | 17,947 | ||||
Supplemental cash flow information | ||||||||
Inventory transferred to property, plant and equipment | $ | 257 | $ | 247 | ||||
Equipment acquired through finance lease liability | $ | — | $ | 98 | ||||
INVESTOR CONTACTS:
George Montague
Chief Financial Officer, Nuwellis, Inc.
ir@nuwellis.com
Matt Bacso
Gilmartin Group
Matt.Bacso@gilmartinir.com
